Sale of Sumavel DosePro Business - Additional Information (Details) - USD ($)		1 Months Ended		12 Months Ended
	May. 16, 2014	Dec. 31, 2014	May. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business				$ 82,984,000	$ 89,624,000	$ 0
Imputed interest on working capital advance				4,615,000
Net gain on sale of business				89,484,000	79,980,000	0
Contract manufacturing revenue				24,369,000	15,392,000	0
Long-term debt interest expense				3,060,000	2,750,000	$ 5,672,000
Notes Payable, Other Payables [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, outstanding	$ 7,000,000
Endo Ventures Supply Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Agreement termination notice period	3 years
Minimum quantity supply period	6 months
Imputed interest on working capital advance				4,748,000
Sumavel DosePro [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business	$ 85,000,000
Escrow deposit	$ 8,500,000
Indemnification period	12 months		12 months
Net product revenue	$ 4,624,000
Cost of goods sold mark-up, in percent	2.50%		2.50%
Contract receivable	$ 9,100,000
Imputed interest on working capital advance	4,748,000
Deferred agreement payments	9,108,000	$ 8,535,000		7,083,000	8,535,000
Net gain on sale of business	79,980,000				79,980,000
Transaction costs	660,000	$ 660,000			660,000
Contract manufacturing revenue				24,369,000	15,392,000
Sumavel DosePro [Member] | Purchasing Entity [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent consideration, additional cash payments	20,000,000
Contingent consideration asset	20,000,000
Sumavel DosePro [Member] | Notes Payable, Other Payables [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, outstanding	7,000,000
Imputed interest on working capital advance	$ 4,748,000
Long-term debt interest expense				$ 375,000	$ 209,000
Minimum [Member] | Endo Ventures Supply Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Term of agreement		8 years